Рекомендации по ведению пациентов с аксиальным спондилоартритом
https://doi.org/10.29235/1814-6023-2019-16-1-117-128
Анатацыя
Спондилоартриты представляют собой группу заболеваний, характеризующихся первично хроническим, прогрессирующим воспалительным процессом с поражением осевого скелета (позвоночника и крестцовоподвздошных сочленений) и периферических суставов, имеющих некоторые общие этиопатогенетические и клинические признаки. Современная концепция спондилоартритов предусматривает выделение преимущественно аксиального и преимущественно периферического вариантов заболевания. Проблема спондилоартритов находится в центре внимания медицинской общественности. Изучению аспектов возникновения и развития заболевания, терапии и профилактики прогрессирования болезни посвящены научные исследования ведущих ревматологических центров. Значительный прогресс достигнут в лечении спондилоартритов. В статье изложены современные рекомендации по ведению пациентов с аксиальным спондилоартритом.
Спіс літаратуры
1. 2016 update of ASAS-EULAR recommendations for axial spondyloarthritis / D. van der Heijde [et al.] // Ann. Rheum. Dis. – 2017. – Vol. 76. – P. 978–991. https://doi.org/10.1136/annrheumdis-2016-210770
2. ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF-therapy / N. Vastesaeger [et al.] // Rheumatol. Clin. – 2014. – Vol. 10, N 4. – P. 204–209. https://doi.org/10.1016/j.reumae.2013.12.025
3. The Assessment of SponyloArthritis intrernational Society (ASAS) handbook: a guide to assess spondyloarthritis / J. Sieper [et al.] // Ann. Rheum. Dis. – 2009. – Vol. 68, suppl. 2. – P. ii1–ii44. https://doi.org/10.1136/ard.2008.104018
4. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis / D. van der Heijde [et al.] // Ann. Rheum. Dis. – 2008. – Vol. 68, N 12. – P. 1811–1818. https://doi.org/10.1136/ard.2008.100826
5. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort / S. Ramiro [et al.] // Ann. Rheum. Dis. – 2014. – Vol. 73, N 8. – P. 1455–1461. https://doi.org/10.1136/annrheumdis-2014-205178
6. Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort / V. Navarro-Compan [et al.] // Ann. Rheum. Dis. – 2015. – Vol. 75, N 5. – P. 874–878. https://doi.org/10.1136/annrheumdis-2015-207786
7. Amor, B. Data management in spondyloarthropathies / B. Amor // Rheumatol. Eur. – 1996. – Vol. 25, N 3. – P. 92–95.
8. Baseline radiographic damage, elevated acte-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondyloarthritis / D. Poddubnyy [et al.] // Arthritis Rheum. – 2012. – Vol. 64, N 5. – P. 1388–1398. https://doi.org/10.1002/art.33465
9. Effcacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1 / J. Sieper [et al.] // Ann. Rheum. Dis. – 2013. – Vol. 73, N 1. – P. 101–107. https://doi.org/10.1136/annrheumdis-2012-203201
10. Bakland, G. Increased mortality in ankylosing spondylitis is related to disease activity / G. Bakland, J. T. Gran, J. C. Nossent // Ann. Rheum. Dis. – 2011. – Vol. 70, N 11. – P. 1921–1925. https://doi.org/10.1136/ard.2011.151191
11. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis / F. Kroon [et al.] // Ann. Rheum. Dis. – 2012. – Vol. 71, N 10. – P. 1623–1629. https://doi.org/10.1136/annrheumdis-2012-201370
12. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from German spondyloarthritis inception cohort / D. Poddubnyy [et al.] // Ann. Rheum. Dis. – 2012. – Vol. 71, N 10. – P. 1616–1622. https://doi.org/10.1136/annrheumdis-2011-201252
13. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomized multicenter trial (ENRADAS) / J. Sieper [et al.] // Ann. Rheum. Dis. – 2015. – Vol. 75, N 8. – P. 1438–1443. https://doi.org/10.1136/annrheumdis-2015-207897
14. Effcacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomized, placeboconrtolled short-term trial / H. Haibel [et al.] // Ann. Rheum. Dis. – 2013. – Vol. 73, N 1. – P. 243–246. https://doi.org/10.1136/annrheumdis-2012-203055
15. Chen, J. Sulfasalazin for ankylosing spondylitis / J. Chen, C. Liu // Cochrane Database Syst. Rev. – 2006. – Vol. 2. – CD004800.
16. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study / S. Arends [et al.] // Arthritis Res. Ther. – 2011. – Vol. 13, N 3. – P. R94. https://doi.org/10.1186/ar3369
17. Five-year follow-up of radiographic sacroiliitis: progression as well as improvement? / A. Sepriano [et al.] // Ann. Rheum. Dis. – 2016. – Vol. 75, N 6. – P. 1262–1263. https://doi.org/10.1136/annrheumdis-2015-208964
18. Effcacy and safety of adalimumab in patients with non-radiographic sxisl spondyloarthritis: results of randomised placebо-controlled trial (ABILITY-1) / J. Sieper [et al.] // Ann. Rheum. Dis. – 2012. – Vol. 72, N 6. – P. 815–822. https://doi.org/10.1136/annrheumdis-2012-20176620
19. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis / J. Sieper [et al.] // Arthritis Rheumatol. – 2015. – Vol. 67, N 10. – P. 2702– 2712. https://doi.org/10.1002/art.39257
20. Effcacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomized placebo-controlled phase 3 study / R. Landewe [et al.] // Ann. Rhum. Dis. – 2013. – Vol. 73, N 1. – P. 39–47. https://doi.org/10.1136/annrheumdis-2013-204231
21. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis / J. Braun [et al.] // Ann. Rheum. Dis. – 2006. – Vol. 65, N 3. – P. 316–320. https://doi.org/10.1136/ard.2005.040758
22. Ankylosing Spondylitis Disease Activity score (ASDAS): defning cut-off values for disease activity states and improvement scoreas / P. Machado [et al.] // Ann. Rheum. Dis. – 2010. – Vol. 70, N 1. – P. 47–53. https://doi.org/10.1136/ard.2010.138594
23. EULAR recommendations for the mahagement of rheumatpod arthritis with synthetic and biological diseasemodifying drugs: 2013 update / J. S. Smolen [et al.] // Ann. Rheum. Dis. – 2014. – Vol. 73. – P. 492–509.
24. Sekukinumab, a human anti-IL A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomized, double-blind placebo-controlled trial / W. Hueber [et al.] // Gut. – 2012. – Vol. 61. – P. 1693–1700.
25. Sekukinumab in plaque psoriasis-results of two phase 3 trials / R. G. Langley [et al.] // N. Engl. J. Med. – 2014. – Vol. 371. – P. 326–338.
26. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial / W. J. Sanborn [et al.] // Gut. – 2007. – Vol. 56, N 9. – P. 1232–1239. https://doi.org/10.1136/gut.2006.106781
27. Adalimumab signifcantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis / J. C. van Denderen [et al.] // J. Rheumatol. – 2014. – Vol. 41, N 9. – P. 1843–1848. https://doi.org/10.3899/jrheum.131289
28. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update / L. Gosses [et al.] // Ann. Rheum. Dis. – 2016. – Vol. 75. – P. 499–510.
29. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis data from the NOR-DMARD register / E. Lie [et al.] // Ann. Rheum. Dis. – 2010. – Vol. 70, N 1. – P. 157–163. https://doi.org/10.1136/ard.2010.131797
30. Sekukinumab effcacy in anti-TNF-naïve and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study / J. Sieper [et al.] // Ann. Rheum. Dis. – 2016. – Vol. 76, N 3. – P. 571–592. https://doi.org/10.1136/annrheumdis-2016-210023
31. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective. Long-term, follow-up study / F. Cantini [et al.] // Biologics. – 2013. – Vol. 7. – P. 1–6. https://doi.org/10.2147/btt.s31474
32. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis; 2 year data of the ESTHER trial / I. H. Song [et al.] // An. Rheum. Dis. – 2012. – Vol. 71, N 7. – P. 1212–1215. https://doi.org/10.1136/annrheumdis-2011-201010
33. Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery / B. Vander Cruyssen [et al.] // Rheumatology (Oxford). – 2009. – Vol. 49, N 1. – P. 73–81. https://doi.org/10.1093/rheumatology/kep174
34. van Royen, B. J. Lumbar osteotomy for correction of thoracolumbar kyphotic deformity in ankylosing spondylitis. A structed review of three methods of treatment / van Royen B. J., de Gast A. // Ann. Rheum. Dis. – 1999. – Vol. 58, N 7. – P. 399–406. https://doi.org/10.1136/ard.58.7.399
35. Westerveld, L. A. Spinal fractures in patients with ankylosing pinal disorders: a systematic review of the literature on treatment, neurological status and complications / L. A. Westerveld, J. J. Verlaan, F. C. Oner // Eur. Spine J. – 2008. – Vol. 18, N 2. – P. 145–156. https://doi.org/10.1007/s00586-008-0764-0
##reviewer.review.form##
Для цытавання:
Кундер Е.В. Рекомендации по ведению пациентов с аксиальным спондилоартритом. Известия Национальной академии наук Беларуси. Серия медицинских наук. 2019;16(1):117-128. https://doi.org/10.29235/1814-6023-2019-16-1-117-128
For citation:
Kundzer A.V. Recommendations on the management of patients with axial spondyloarthritis. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2019;16(1):117-128. (In Russ.) https://doi.org/10.29235/1814-6023-2019-16-1-117-128
Праглядаў: 838
Паслаць артыкул па эл. пошце 